Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Stereotactic fractionated photon radiotherapy: Results (n = 24)

From: Linear accelerator-based stereotactic fractionated photon radiotherapy as an eye-conserving treatment for uveal melanoma

Radiotherapy dose in BED
 Median 78 Gy
 Range 37.5–131.25 Gy
Follow up 5.2 years
  n %
Linear accelerator-based fractionated photon radiotherapy
 Primary irradiation 24 100
 Re-irradiation 2 8.3
Local response
 Complete remission 1 4.2
 Partial remission 8 33.3
 Stable disease 11 45.8
 Progressive disease 4 16.7
Enucleation rate 5 20.9
 Due to grade 4 toxicity 4 16.7
 Due to recurrence 1 4.2
Eye conservation 19 79.1
Blindness before radiotherapy (n = 24) 4 16.7
Blindness after 24 months (n = 20)
 Due to grade 4 toxicity 5 25.0
 Due to recurrence 0 0